Print this page
-
First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in
Participants with B-cell Malignancies
Protocol: 012321Principal Investigator:
- Joanna Rhodes MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase 1/2, First in Human Study of DCC-3116 as Monotherapy and in Combination with RAS/MAPK Pathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations
Protocol: 052308Principal Investigator:
- Sanjay Goel (Rutgers University)
Applicable Disease Sites: Any Site -
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants with Advanced Malignancies
Protocol: 052310Principal Investigator:
- Sanjay Goel (Rutgers University)
Applicable Disease Sites: Any Site -
NCI 10204 - A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Protocol: 092305Principal Investigator:
- Sarah Weiss MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Melanoma, Skin -
A First-in-Human Study of Mutant-selective PI3K alpha; Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer
Protocol: 042402Principal Investigator:
- Mridula George (Rutgers University)
Applicable Disease Sites: Breast -
A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation with Enrichment and
Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics,
Pharmacodynamics, and Antitumor activity of GIM-122 as a Single Agent in Adult
Subjects with Advanced Solid Malignancies
Protocol: 052401Principal Investigator:
- Sanjay Goel (Rutgers University)
Applicable Disease Sites: Any Site